A US Food and Drug Administration perspective on evaluating medical products for Ebola

被引：9
|
作者：
Russek-Cohen, Estelle [1 ]
Rubin, Daniel [2 ]
Price, Dionne [2 ]
Sun, Wellington [1 ]
Cox, Edward [2 ]
Borio, Luciana [3 ]
机构：
[1] US FDA, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[2] US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[3] US FDA, Off Commissioner, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
来源：
CLINICAL TRIALS | 2016年 / 13卷 / 01期
关键词：
Therapeutic clinical trials; vaccine clinical trials; Ebola; SIERRA-LEONE; VACCINE; TRIALS;
D O I：
10.1177/1740774515620613
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：105 / 109
页数：5
相关论文
共 50 条
  • [41] When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective
    Huang, S-M
    Temple, R.
    Xiao, S.
    Zhang, L.
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (05) : 475 - 479
  • [42] US Food and Drug Administration's Approval of Aripiprazole Tablets With Sensor: Our Perspective
    Lee, Daniel J.
    Farchione, Tiffany R.
    Mathis, Mitchell V.
    Muniz, Javier
    Muoio, Brendan M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2018, 79 (03)
  • [43] Evaluation of epinephrine's expiration date: A US Food and Drug Administration's perspective
    Lan, Jennifer
    Paterniti, Miya
    Bertha, Craig
    Pinto, Julia
    Randazzo, Giuseppe
    Sood, Ramesh
    Seymour, Sally
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (08): : 2948 - 2948
  • [44] FOOD AND DRUG ADMINISTRATION - APPROACH TO EVALUATING NEUROTOXICITY
    SOBOTKA, TJ
    TOXICOLOGY AND INDUSTRIAL HEALTH, 1989, 5 (02) : 157 - 164
  • [45] Primer on medical device regulation .2. Regulation of medical devices by the US Food and Drug Administration
    Monsein, LH
    RADIOLOGY, 1997, 205 (01) : 10 - 18
  • [46] The US Food and Drug Administration's Approach for Safe Innovation of Medical Devices in Dermatology
    Chang, Cynthia J.
    Ashar, Binita S.
    Marquart, Laura N.
    JAMA DERMATOLOGY, 2018, 154 (03) : 261 - 263
  • [47] Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA)
    Weaver, Joyce
    La Grenade, Lois
    Kwon, Hyon
    Avigan, Mark
    DERMATOLOGIC THERAPY, 2009, 22 (03) : 204 - 215
  • [48] Surgical Innovation and the US Food and Drug Administration
    Cundiff, Geoffrey W.
    FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2019, 25 (04): : 263 - 264
  • [49] US Food and Drug Administration pushed to change
    McCarthy, M
    LANCET, 2006, 367 (9523): : 1643 - 1644
  • [50] Increasing Transparency at the US Food and Drug Administration
    Steinbrook, Robert
    JAMA INTERNAL MEDICINE, 2019, 179 (08) : 1146 - 1147
12345